title: The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity.
abstract: OBJECTIVE
  To determine the effect of two weeks preoperative finasteride therapy in reducing prostate vascularity in terms of mean microvessel density (MVD) and expression of VEGF in prostate urothelium among patients of BPH by comparing with controls.
  
  
  METHODS
  Randomized controlled trial.
  
  
  METHODS
  Shifa International Hospital, Islamabad, from January 2013 to January 2014.
  
  
  METHODS
  A total of 80 patients of Benign Prostatic Hyperplasia (BPH) planned for Trans-Urethral Resection of Prostate (TURP) having prostate size of more than 40 grams on trans-abdominal ultrasonography was randomized into two groups, each group having 40 patients. The finasteride group (Group A) was prescribed oral 5 mg of finasteride daily for 2 weeks before surgery. The control group (Group B) did not receive any agent. After 2 weeks, TURP was performed and prostate samples were sent for histopathological determination of MVD and expression of VEGF.
  
  
  RESULTS
  The mean age of patients was 66.21 ±10.08 years, ranging from 48 to 86 years. The mean prostate gland size was comparable in both groups (55 ±10.7 vs. 58.1 ±10.8 grams, p=0.21). Mean MVD in finasteride group (20.25 ±10.3) was significantly lower as compared to control group (48.9 ±22.6, p < 0.001). Similarly expression of VEGF was also significantly lower in finasteride group (30%) as compared to control group (65%) [p= 0.0017]. Mean MVD had a significant weak correlation with the size of prostate gland on Pearson correlation test (2-tailed) with r = 0.222.
  
  
  CONCLUSIONS
  Finasteride reduces microvessel density and hence prostate vascularity with only 2-week therapy and the mean MVD is clearly correlated with size of prostate.
authors.affiliation: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad.
authors.forename: Muhammad Athar
authors.initials: MA
authors.lastname: Khwaja
authors.affiliation: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad.
authors.forename: Gul
authors.initials: G
authors.lastname: Nawaz
authors.affiliation: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad.
authors.forename: Shujah
authors.initials: S
authors.lastname: Muhammad
authors.affiliation: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad.
authors.forename: Muhammad Imran
authors.initials: MI
authors.lastname: Jamil
authors.affiliation: Department of Pathology, Shifa International Hospital, Islamabad.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Faisal
authors.affiliation: Department of Urology and Kidney Transplant, Shifa International Hospital, Islamabad.
authors.forename: Saeed
authors.initials: S
authors.lastname: Akhter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D011467:Prostate / Q000098:blood supply*; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D004791:Enzyme Inhibitors; D042461:Vascular Endothelial Growth Factor A; D018120:Finasteride